THIS ANNOUNCEMENT, INCLUDING THE APPENDIX AND INFORMATION
CONTAINED HEREIN, IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION
OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN,
INTO OR FROM THE UNITED
STATES, CANADA, JAPAN, AUSTRALIA, NEW ZEALAND,
THE REPUBLIC OF SOUTH AFRICA, THE REPUBLIC OF IRELAND,
ANY MEMBER STATE OF THE EEA OR ANY OTHER JURISDICTION WHERE TO DO
SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS
OF THAT JURISDICTION. PLEASE SEE THE IMPORTANT NOTICES AT THE END
OF THIS ANNOUNCEMENT.
THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND SHALL
NOT CONSTITUTE AN OFFER TO SELL OR ISSUE OR THE SOLICITATION OF AN
OFFER TO BUY, SUBSCRIBE FOR OR OTHERWISE ACQUIRE ANY NEW ORDINARY
SHARES OF CPH2 IN THE UNITED
STATES, CANADA, JAPAN, AUSTRALIA, NEW ZEALAND,
THE REPUBLIC OF SOUTH AFRICA, THE REPUBLIC OF
IRELAND, ANY MEMBER STATE OF THE EEA OR ANY OTHER JURISDICTION IN
WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE
UNLAWFUL.
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS DEFINED IN
ARTICLE 7 OF THE MARKET ABUSE REGULATION EU NO. 596/2014, AS
RETAINED AND APPLICABLE IN THE UK PURSUANT TO S3 OF THE
EUROPEAN UNION (WITHDRAWAL) ACT 2018 ("MAR"). UPON THE PUBLICATION
OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION IS NOW CONSIDERED TO
BE IN THE PUBLIC DOMAIN.
26
November
2024
Clean Power Hydrogen
plc
("CPH2", the "Company" or the
"Group")
Operational & Strategic
Update and Proposed Fundraising
CPH2, the UK-based green hydrogen
technology and manufacturing company that has developed the
IP-protected Membrane-Free Electrolyser ("MFE"), is pleased to provide an update
on current operational activities and strategy.
Following the announcement of the
successful Factory Acceptance Test ("FAT") of its MFE110 unit in September,
which confirmed the first customer acceptance and validation of the
Company's unique scaled electrolyser technology, the Company is now
moving into the next stage of its development and is targeting the
full commercialisation of its flagship MFE220 unit and the
generation of first revenues in 2025.
CPH2 currently has contracts for the
sale of four MFE220 units, with one unit to be deployed to Belfast
for Northern Ireland Water ("NIW"), two further units to Fabrum
Solutions Limited in New Zealand ("Fabrum") and, as announced most
recently, one unit to Lisheen H2 Energy Park Limited, which trades
under the name Hidrigin, in Ireland ("Hidrigin"). In addition, CPH2 has
licence agreements in place with Fabrum, Hidrigin and Kenera Energy
Solutions Limited ("Kenera"), a business unit within
leading drilling, engineering and technology company, KCA Deutag,
which enable CPH2 to rapidly scale up to meet demand for its MFE
technology across multiple geographies.
The Board is focused on establishing
the optimal strategy to enable the commercialisation of its unique
and highly scalable MFE product and is seeking to implement a
business model which builds CPH2's in-house manufacturing
capability alongside the activation of the three existing licensees
and which results in a flexible, capital-light model that
prioritises capital efficiency and sustainable growth to optimise
value for shareholders.
The Company's short-term activities
are aimed at deploying the initial MFE110 unit to NIW and
completing the design and optimisation of the MFE220. The first
MFE220 electrolyser will be built for NIW, followed by the Hidrigin
unit and the two units for Fabrum. During the next 18 months the
Company also intends to fully activate its various licensees and
build out its commercial team. These activities are to prepare the
Company for increasing its manufacturing capability in late 2026 as
it moves into the scale phase of the commercialisation
pathway.
A copy of the Company's latest
corporate presentation is available on the Company's website at
www.cph2.com/investors/.
Proposed
Fundraising
In order to fund the implementation
of this strategy, the Company is proposing to raise a minimum of
£6m by way of a fundraising (the "Fundraising") of new ordinary shares in
the capital of the Company (the "New Shares") at a proposed price of 7.5
pence per New Share (the "Issue
Price"), which represents a discount of 20.8 per cent. to
the volume weighted average price of the Company's shares in the 20
trading days prior to 25 November 2024 (being the last business day
prior to this announcement) and a discount of 2 per cent. to the
closing middle market price of 7.65 pence on that date.
The Fundraising is expected to be
carried out by way of a subscription, a placing (by way of an
accelerated book build process) and a retail offer via the
Bookbuild platform in order to enable the Company's retail
shareholder base to participate and to continue to support its
growth strategy (the "Retail
Offer"). Further details of the Fundraising will be
announced in due course.
The Company has received expressions
of interest from certain existing shareholders and other investors,
including Kenera and a number of the directors of CPH2, to
participate in the Fundraising at the Issue Price.
The net proceeds of the Fundraising
will be used to fund its working capital requirements through to
the FAT of its first commercial MFE220 unit and, during that time,
also to facilitate the:
· shipping, installation and commissioning of MFE110 to NIW;
and
· finalisation of MFE220 design.
Any additional proceeds raised
pursuant to the Fundraising will provide additional working capital
support and further strengthen the balance sheet.
Whilst the Company has received
non-binding indications of interest, there can be no certainty at
this time that the Fundraising will complete on the proposed terms
or at all. Shareholders should note that, in the event that the
Fundraising is not successful and alternative funding is not made
available, the amount of working capital available to the Company
will be severely limited. There is no certainty that other funding
would be available on suitable terms or at all. Accordingly, in
light of the Company's existing cash position, it would be likely
that the Company would have to severely restrict its costs,
impacting its ability to continue its operations during 2025 and to
progress its growth strategy.
Jon
Duffy, CEO of Clean Power Hydrogen commented:
"This operational and strategic update highlights our
dedication to delivering innovative, scalable solutions while
maintaining a disciplined, efficient approach to growth and
commercialisation. Deploying the MFE110 to Northern Ireland Water
and advancing the MFE220 design are key steps on our path to full
commercialisation of our technology. The proposed Fundraising will
provide the necessary resources to drive these initiatives forward
and support our sustainable growth
ambitions."
ENDS
For
more information, please contact:
Clean Power Hydrogen plc
|
via Camarco
|
Jon Duffy, Chief Executive
Officer
|
|
James Hobson, Chief Financial
Officer
|
|
|
|
Cavendish Capital Markets Limited - NOMAD &
Broker
|
|
Neil McDonald
|
+44 (0)131 220 9771
|
Peter Lynch
|
+44 (0)131 220 9772
|
Adam Rae
|
+44 (0)131 220 9778
|
|
|
Camarco PR
|
+ 44(0) 20 3757 4980
|
Billy Clegg
|
|
Owen Roberts
|
|
Lily Pettifar
|
|
To find out more, please
visit: https://www.cph2.com
Overview of CPH2
CPH2 is the holding company of Clean
Power Hydrogen Group Limited which has almost a decade of dedicated
research and product development experience. This experience has
resulted in the creation of simple, safe and sustainable technology
which is designed to deliver a modular solution to the hydrogen
production market in a cost-effective, scalable, reliable and
long-lasting manner. The Group's strategic objective is to deliver
the lowest LCOH in the market in relation to the production of
green hydrogen. CPH2 is listed on the AIM market and trades under
the ticker LON:CPH2.
Forward-Looking Statements
This announcement contains
forward-looking statements. These statements relate to the Group's
future prospects, developments and business strategies.
Forward-looking statements are identified by their use of terms and
phrases such as "potential", "estimate", "expect", "may", "will" or
the negative of such terms and phrases, variations or comparable
expressions, including references to assumptions. The
forward-looking statements in this announcement are based on
current expectations and are subject to risks and uncertainties
that could cause actual results to differ materially from those
expressed or implied by those statements. These forward-looking
statements speak only as at the date of this announcement. No
statement in this announcement is intended to constitute a profit
forecast or profit estimate for any period. No representation or
warranty is given as to the completeness or accuracy of the
forward-looking statements contained in this Announcement.
Neither the Directors nor the Company undertake any
obligation to update forward-looking statements other than as
required by the AIM Rules or by the rules of any other securities
regulatory authority, whether as a result of new information,
future events or otherwise.
Market Abuse Regulation
Market soundings, as defined in MAR,
were taken in respect of the Fundraising, with the result that
certain persons became aware of inside information, as permitted by
MAR. That inside information is set out in this announcement and
has been disclosed as soon as possible in accordance with paragraph
7 of article 17 of MAR. Therefore, those persons that received
inside information in a market sounding are no longer in possession
of inside information relating to the Company and its
securities.